Skip to main content

Advertisement

SpringerLink
Log in

Patient-reported outcome measures after 8 weeks of mepolizumab treatment and long-term outcomes in patients with severe asthma: an observational study

  • Short Research Report
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background The novel anti-IL-5 drug mepolizumab improves asthma outcomes in the majority but not all patients with severe eosinophilic asthma. Currently it is difficult to predict an individuals’ chance of being a responder. Early changes in patient-reported outcome measures may contribute to the prediction of long-term outcomes. Aim To compare early changes in patient-reported outcome measures after 8 weeks and long-term response to mepolizumab treatment. Method 22 severe eosinophilic asthma patients starting mepolizumab therapy in a severe asthma centre in the Netherlands were evaluated on baseline, 8 weeks and 52 weeks, collecting questionnaire scores and asthma-related parameters. Well-controlled asthma was defined as an asthma control questionnaire score ≤ 0.75. Long-term treatment response was defined as continuing mepolizumab therapy at 52 weeks. Results Nine patients (41%) had well-controlled asthma at 8 weeks and all were mepolizumab responders at 52 weeks (positive predictive value = 100%, 95%CI 66–100), versus only 5 responders out of 13 patients with not well-controlled asthma at 8 weeks (negative predictive value = 62%, 95%CI 32–86). Conclusion The results in this study suggest that patients receiving mepolizumab therapy with an ACQ-score ≤ 0.75 at 8 weeks are unlikely to need extensive monitoring, for they are very likely to be long-term responders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Eger K, Kroes JA, Ten Brinke A, et al. Long-term therapy response to anti-IL-5 biologics in severe asthma-A real-life evaluation. J Allergy Clin Immunol Pract. 2020. S2213-2198(20)31121-1.

  2. Kroes JA, Zielhuis SW, van Roon EN, et al. Prediction of response to biological treatment with monoclonal antibodies in severe asthma. Biochem Pharmacol. 2020. S0006-2952(20)30206-9.

  3. Juniper EF, Buist AS, Cox FM, et al. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999. S0012-3692(15)35278-8.

  4. Juniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999. https://doi.org/10.1034/j.1399-3003.1999.14d29.x.

    Article  PubMed  Google Scholar 

  5. Boer S, Sont JK, Loijmans RJB, et al. Development and validation of personalized prediction to estimate future risk of severe exacerbations and uncontrolled asthma in patients with asthma, using clinical parameters and early treatment response. J Allergy Clin Immunol Pract. 2019. S2213–2198(18)30397–0.

  6. Global Initiative for Asthma (2021) Difficult-to-treat & severe asthma in adolescent and adult patiens. In: https://ginasthma.org/wp-content/uploads/2021/08/SA-Pocket-guide-v3.0-SCREEN-WMS.pdf. Accessed 13 Sep 2021.

  7. Juniper EF, Bousquet J, Abetz L, et al. Identifying 'well-controlled' and 'not well-controlled' asthma using the asthma control questionnaire. Respir Med. 2006. S0954-6111(05)00335-5.

  8. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012. https://doi.org/10.1016/S0140-6736(12)60988-X.

    Article  PubMed  Google Scholar 

  9. Numata T, Miyagawa H, Kawamoto H, et al. Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: a retrospective, long-term study. Cogent Med. 2020. https://doi.org/10.1080/2331205X.2020.1776468.

    Article  Google Scholar 

  10. Hough KP, Curtiss ML, Blain TJ, et al. Airway Remodeling in Asthma. Front Med. 2020.

Download references

Acknowledgements

Not Applicable

Funding

This study was supported by funding of the Medical Centre Leeuwarden Science Fund, the Netherlands.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, The Netherlands

    Johannes Anthon Kroes, Sander Wilhelm Zielhuis & Eric Nico van Roon

  2. Department of Pulmonary Diseases, Medical Centre Leeuwarden, Leeuwarden, the Netherlands

    Akke-Nynke van der Meer & Anneke ten Brinke

  3. Department of Epidemiology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands

    Kim de Jong

  4. Unit of Pharmacotherapy, Epidemiology and Economics, Department of Pharmacy, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands

    Eric Nico van Roon

Authors
  1. Johannes Anthon Kroes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sander Wilhelm Zielhuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akke-Nynke van der Meer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kim de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anneke ten Brinke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eric Nico van Roon
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.A. Kroes Wrote manuscript, Designed Research, Performed Research, Analyzed Data. S.W. Zielhuis Wrote manuscript, Designed Research. A.N. van der Meer Wrote manuscript, Designed Research. K. de Jong Wrote manuscript, Designed Research, Analyzed Data. A. ten Brinke Wrote manuscript, Designed Research. E.N. van Roon Wrote manuscript, Designed Research.

Corresponding author

Correspondence to Johannes Anthon Kroes.

Ethics declarations

Conflict of interest

Mr. Kroes reports grants from Astra Zeneca, outside the submitted work. Dr. Zielhuis reports grants from Astra Zeneca, personal fees from Novartis, personal fees from GSK, personal fees from Sanofi, personal fees from Lilly, personal fees from MSD, outside the submitted work. Dr. van der Meer has nothing to disclose. Dr. de Jong has nothing to disclose. Dr. Ten Brinke reports grants, personal fees and other from GSK, grants, personal fees and other from TEVA, grants, personal fees and other from AstraZeneca, other from Sanofi, other from Boehringer Ingelheim, outside the submitted work. Dr. Van Roon has nothing to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kroes, J.A., Zielhuis, S.W., van der Meer, AN. et al. Patient-reported outcome measures after 8 weeks of mepolizumab treatment and long-term outcomes in patients with severe asthma: an observational study. Int J Clin Pharm 44, 570–574 (2022). https://doi.org/10.1007/s11096-021-01362-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-021-01362-8

Keywords

Search

Navigation